Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PURCHASES REFLECT STRONG CONFIDENCE IN THE SCIENTIFIC DIFFERENTIATION AND COMMERCIAL POTENTIAL OF ATEGANOSINE CHICAGO, DEC. 24, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC. (NYSE AMERICAN: MAIA) (MAIA, THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED THAT INDEPENDENT DIRECTORS INCLUDING ADELINA LOUIE NGAR YEEAND STAN V. SMITH, PH.D.

MAIA BIOTECHNOLOGY BOARD MEMBERS CONTINUE TO PARTICIPATE IN PRIVATE PLACEMENT FINANCINGS

CHICAGO, IL, DEC. 16, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC., (NYSE AMERICAN: MAIA) (MAIA, THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 1,233,488 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $1.224 PER SHARE, IN A PRIVATE PLACEMENT TO ACCREDITED INVESTORS AND A COMPANY DIRECTOR. EACH SHARE OF COMMON STOCK IS BEING OFFERED TOGETHER WITH A WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK AT AN EXERCISE PRICE OF $1.36 PER SHARE, WHICH PRICE REPRESENTS THE MINIMUM PRICE AS DEFINED UNDER NYSE AMERICAN RULE 713 (SUBJECT TO CUSTOMARY ADJUSTMENTS AS SET FORTH IN THE WARRANTS). THE WARRANTS ARE EXERCISABLE COMMENCING SIX-MONTHS FOLLOWING ISSUANCE AND HAVE A TERM OF THREE YEARS FROM THE ISSUANCE DATE. THE SECURITIES BEING SOLD TO THE COMPANY DIRECTOR PARTICIPATING IN THE OFFERING ARE BEING ISSUED PURSUANT TO THE COMPANY'S 2021 EQUITY INCENTIVE PLAN. THE PRIVATE PLACEMENT IS EXPECTED TO CLOSE ON OR ABOUT DECEMBER 18, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

MAIA BIOTECHNOLOGY ANNOUNCES $1.51 MILLION PRIVATE PLACEMENT

CHICAGO, DEC. 11, 2025 (GLOBE NEWSWIRE) -- ATEGANOSINE (THIO, 6-THIO-2'-DEOXYGUANOSINE), A FIRST-IN-CLASS TELOMERE-TARGETING THERAPY UNDER DEVELOPMENT BY MAIA BIOTECHNOLOGY (NYSE AMERICAN: MAIA), APPEARS TO BE GAINING INCREASING ATTENTION IN THE ONCOLOGY COMMUNITY AS EMERGING CLINICAL RESULTS CONTINUE TO SURPASS EXPECTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). WITH THE THERAPY'S PHASE 2 TRIAL ONGOING AND A PIVOTAL PHASE 3 PROGRAM INITIATED THIS WEEK, ATEGANOSINE IS BEING CLOSELY WATCHED AS ONE OF THE MOST DISTINCTIVE INVESTIGATIONAL APPROACHES IN SOLID-TUMOR TREATMENT TODAY.

MAIA'S ATEGANOSINE SURGES AHEAD WITH BREAKTHROUGH MOMENTUM AS PIVOTAL PHASE 3 TRIAL INITIATES

KEY MILESTONE ACHIEVED AS COMPANY ADVANCES CLINICAL PROGRAM TO FULL APPROVAL TRIAL OF ATEGANOSINE SEQUENCED WITH A CHECKPOINT INHIBITOR IN COMPARISON TO CHEMOTHERAPY CHICAGO, DEC. 11, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC. (NYSE AMERICAN: MAIA) ("MAIA", THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE COMPANY'S THIO-104 PHASE 3 PIVOTAL TRIAL EVALUATING THE EFFICACY OF ATEGANOSINE ADMINISTERED IN SEQUENCE WITH A CHECKPOINT INHIBITOR (CPI) AS A THIRD-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).

MAIA BIOTECHNOLOGY ANNOUNCES FIRST PATIENT DOSED IN THIO-104 PHASE 3 PIVOTAL TRIAL EVALUATING ATEGANOSINE AS THIRD-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER

CHICAGO, DEC. 10, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY (NYSE AMERICAN: MAIA)  THE TREATMENT PARADIGM FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IS UNDERGOING ANOTHER SHIFT. AFTER A DECADE OF TARGETED THERAPIES AND CHECKPOINT INHIBITORS (CPIS) DOMINATING HEADLINES, MAIA BELIEVES THAT A NEW THERAPEUTIC CLASSTELOMERE-TARGETING AGENTSIS EMERGING FOR THE POPULATION WITH SUBSTANTIAL UNMET MEDICAL NEED: PATIENTS WITHOUT ACTIONABLE MUTATIONS AND WHO NO LONGER RESPOND TO CPIS OR CHEMOTHERAPY.

MAIA TAKES AIM AT A $50B IMMUNOTHERAPY MARKET WITH BREAKTHROUGH TELOMERE-TARGETING APPROACH

CHICAGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC. (NYSE AMERICAN: MAIA) (MAIA, THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED THAT THE CEO AND CERTAIN MEMBERS OF THE COMPANY'S BOARD OF DIRECTORS PURCHASED APPROXIMATELY 182,445 SHARES OF MAIA COMMON STOCK AT MARKET PRICE BETWEEN NOVEMBER 21 AND 28, 2025. THE AVERAGE COMMON STOCK PRICE WAS $1.06.

MAIA BIOTECHNOLOGY ANNOUNCES OPEN MARKET PURCHASES BY CEO AND DIRECTORS

COMPANY CONFIRMS 12 PATIENTS ENROLLED IN PHASE 2 THIO-101 TO DATE AS EXPANSION TRIAL ADDS NEW COUNTRIES

MAIA BIOTECHNOLOGY HIGHLIGHTS ONGOING MOMENTUM OF ATEGANOSINE CLINICAL PROGRAM AT SITC 2025

NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND EQUITY RESEARCH, A LEADING EQUITY RESEARCH FIRM WITH A FOCUS ON SMALL CAPITALIZATION PUBLIC COMPANIES HAS RELEASED AN UPDATE NOTE ON MAIA BIOTECHNOLOGY, INC. (NYSE: MAIA) FOLLOWING QUARTERLY RESULTS. THE RESEARCH SUMMARY BELOW IS FROM A REPORT COMMISSIONED BY MAIA BIOTECHNOLOGY, INC. AND PRODUCED BY DIAMOND EQUITY RESEARCH.

DIAMOND EQUITY RESEARCH RELEASES UPDATE NOTE ON MAIA BIOTECHNOLOGY, INC. (NYSE: MAIA)

FIRST FIVE PATIENTS IN PART C (EXPANSION) OF THIO-101 PHASE 2 CLINICAL TRIAL ENROLLED IN TAIWAN AND TURKEY

MAIA BIOTECHNOLOGY PRESENTS TRIAL IN PROGRESS POSTER AT THE 2025 AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

CHICAGO, OCT. 23, 2025 (GLOBE NEWSWIRE) -- MAIA BIOTECHNOLOGY, INC. (NYSE AMERICAN: MAIA) (MAIA, THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING TARGETED IMMUNOTHERAPIES FOR CANCER, TODAY ANNOUNCED HIGHLIGHTS FROM A RECENT PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025 HELD IN BERLIN, GERMANY. STARTING OCTOBER 19, 2025, MAIA SHOWCASED TWO E-POSTERS AT ESMO DETAILING ITS ONGOING PHASE 2 AND PHASE 3 CLINICAL TRIALS OF ATEGANOSINE IN NON-SMALL CELL LUNG CANCER (NSCLC).

MAIA Biotechnology, Inc.

MAIA

Price

Financial Reports

No items found.

Press Releases

MAIA Biotechnology, Inc.

MAIA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MAIA